img click



img Focus Areas
img Pipeline
arrow PluraStem™
arrow ImmuStem™
arrow MesoStem™
arrow AlloGraf™
arrow GlucoStem™
arrow MorphoGel™
arrow FibroStem™
arrow Neurox™
arrow OsteoStem™
img Intellectual Property
img Publications


PluraStem™ utilizes its platform IT™ technology to create the world's first universal pluripotent stem cell source. Human ESCs are an ideal tissue source for cell replacement therapy. They have the potential for limitless self-renewal while retaining their ability to differentiate into a wide variety of cells and tissues. Since their first derivation in 1998, ESCs have been used in many studies in order to evaluate their potential therapeutic utility in humans. These have included animal models of myocardial infarction, Parkinson's disease, spinal cord injury, and bone marrow deficiency. Results so far have been promising, and many groups are advancing studies in support of clinical trials of ESC-derived cells. However, these studies have depended on either the use of immunosuppressed animals to avoid allogeneic or xenogeneic graft rejection or the coadminstration of highly toxic immunosuppressive drugs. Thus, a key limitation in transplanting ESC-derived cells remains their potential to elicit a host immune response with subsequent graft rejection due to immune mismatch between host and donor cells. In fact, recent studies showed that a single minor histocompatability antigen mismatch led to the rejection of allogeneic ESCs. In order to realize the enormous clinical promise of ESCs, novel cell lines capable of evading immune rejection by immunocompetent hosts are desperately needed.

Escape has been focused on addressing this critical unmet need, and has had preliminary success in developing and validating an immune override mechanism for human adult stem cells and somatic cells. We accomplished this through our innovative platform technology called IT™, a tolerogenic molecule that confers immune protection to cells expressing it on their extracellular membranes. Escape believes IT™ will reduce or completely obviate the need for adjunctive immunosuppression, a dreaded class of drugs with serious side effects that is currently required to avoid donor rejection. Escape's PluraStem™ line will allow the creation of off-the-shelf ESC-derived cell replacement therapies for use in patients of any HLA type without the need for adjunctive immunosuppression, HLA matching, or autologous sourcing.

2010 Escape Therapeutics, Inc. All rights reserved.

Website design by Sylvia Do & Chris Nye